Skip to main content
Premium Trial:

Request an Annual Quote

Montreal Heart Institute Developing Cardiac Screening Panel for GnuBio Sequencer

NEW YORK (GenomeWeb News) — GnuBio said today that it is collaborating with the Montreal Heart Institute to develop a genetic panel that will run on the GnuBio platform and predict the risk of sudden cardiac death.

The partners plan to use GnuBio's microfluidics-based sequencing system to develop and validate a set of genes related to sudden cardiac death. "The result will be a clinically validated test the can be used to assess the risk of SCD in susceptible patients on a sequencing platform that will significantly reduce the time from patient to result," the company said in a statement.

As reported by GenomeWeb Daily News sister publication In Sequence, GnuBio plans to launch its sequencer commercially in the second quarter of this year. The system will have a list price of $50,000 and the turnaround time for a targeted sequencing run is expected to be around two hours.

The Montreal Heart Institute is an early-access customer for the GnuBio sequencer. It received the system last summer.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.